Shopping Cart
- Remove All
Your shopping cart is currently empty
SEP-363856 hydrochloride (SEP-856 hydrochloride) is an orally active, CNS-active psychotropic agent with a unique non-D2/5-HT2A mechanism of action, demonstrating antipsychotic-like effects and potential for schizophrenia treatment.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $64 | In Stock | |
| 2 mg | $93 | In Stock | |
| 5 mg | $156 | In Stock | |
| 10 mg | $255 | In Stock | |
| 25 mg | $448 | In Stock | |
| 50 mg | $662 | In Stock | |
| 100 mg | $987 | In Stock | |
| 500 mg | $1,980 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $172 | In Stock |
| Description | SEP-363856 hydrochloride (SEP-856 hydrochloride) is an orally active, CNS-active psychotropic agent with a unique non-D2/5-HT2A mechanism of action, demonstrating antipsychotic-like effects and potential for schizophrenia treatment. |
| Targets&IC50 | 5-HT2C receptor:30 μM (EC50), TAAR1:0.140 μM (EC50), 5-HT7 receptor:6.7 μM (EC50), 5-HT1B receptor:15.6 μM (EC50), 5-HT2A receptor:10 μM (EC50), 5-HT1D receptor:0.262 μM (EC50), 5-HT1A receptor:2.3 μM (EC50) |
| In vitro | SEP-856 (10μM) specifically inhibits α2A, α2B, D2, 5-HT1A, 5-HT1B, 5-HT1D, 5-HT2A, 5-HT2B, 5-HT2C and 5-HT7> 50% receptor. |
| In vivo | SEP-856 (0.3, 1, and 10 mg/kg, i.p.) is CNS active and exhibits a behavioral signature similar to known antipsychotic drugs. PCP-induced hyperactivity is significantly reduced by SEP-856 (0.3, 1, and 10 mg/kg, orally once). Oral SEP-856 administration (1, 3, and 10 mg/kg) produces a dose-dependent decrease in REM sleep, increase in latency to REM sleep, and increase in cumulative wake (W) time. |
| Synonyms | SEP-856 hydrochloride |
| Molecular Weight | 219.73 |
| Formula | C9H14ClNOS |
| Cas No. | 1310422-41-3 |
| Smiles | Cl.CNC[C@@H]1OCCc2ccsc12 |
| Relative Density. | no data available |
| Color | White |
| Appearance | Solid |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 55 mg/mL (250.31 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (22.76 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.